EXPLORING THE HETEROGENEITY OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A LATENT CLASS ANALYSIS

Background: Based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019, stable Chronic Obstructive Pulmonary Disease (COPD) patients group B is given long-acting beta-2 agonist (LABA) or long-acting anticholinergic (LAMA).Some studies experience LAMA is better than LABA but the opposite is also found in several studies.COPD patients often experience decrease in physical activity which causes a decrease in quality of life.BODE index is a parameter used to determine the prognosis of COPD.We aimed to compare the effect of LABA or LAMA on BODE index and quality of life in stable COPD patients group B.Methods: This was a case series design study conducted on 50 COPD patients divided into two groups.The first group is patients who use LABA for a minimum of 3 months, the second group is LAMA for a minimum of 3 months.All subjects performed spirometry examinations, BMI measurements, MMRC, 6 minutes walking test and filled in the SGRQ questionnaire.The calculation of the SGRQ questionnaire is done with Microsoft Excel Calculator SGRQ.Statistical analysis was carried out by using statistical software.Results: A total 41 men and 9 women were enrolled in this study.There was no significant difference in BODE index between LABA or LAMA users (p = 0.269).Thus, there was no difference effect to quality of life (p = 0.538) Conclusion: There was no significant difference in prognosis between using LABA or LAMA in stable COPD patients group B. And there was no difference in quality of life between using LABA or LAMA in stable COPD patients group B.